Immunome clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282AL102Active not recruiting2025-12-03Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-04-28DayAL102Immunome, Inc. · IMNMCompany-disclosed PDUFA goal dateAnnounced review targetNot specifiedOpen original source
Read source excerpt

an NDA for varegacestat to the FDA, which was assigned a PDUFA target action date of April 28, 2027

First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026

2027-04-28DayAL102Immunome, Inc. · IMNMCompany-disclosed PDUFA goal dateAnnounced review targetNot specifiedOpen original source
Read source excerpt

Varegacestat PDUFA target action date of April 28, 2027

First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival. After: Measure: Part A: Safety and Tolerability - Adverse Events Measure: Part B: Progression free survival (PFS).

Check registry source